Apollo, the world's largest integrated healthcare provider, announced its position as the largest Cardiac care program in India and one of the leading cardiac programs in the world in terms of scale, outcomes, complexity, diversity and access. Apollo's unparalleled clinical excellence is built on extensive experience of performing over 300,000 angioplasties and 200,000 cardiac surgeries and providing the full spectrum of cardiac care services.

The Cardiac Center of Excellence at Apollo Hospitals stands as a testament to the institution's leadership, state-of-the-art facilities, exceptional clinical team, and ground-breaking technologies. Spanning across 38 hospitals with 375+ consultants, Apollo is the first corporate hospital group and largest private tertiary care institution for cardiovascular sciences in India. It attracts patients across the globe (from over 140 countries) for best-in-class outcomes compared to international benchmarks and seamless service delivery at affordable price points.

The clinical offering at Apollo is one of the most comprehensive in the world, providing treatment for coronary artery disease, structural heart disease, congenital heart conditions and heart failure through advanced modalities ranging from minimally invasive and robot assisted surgery, to technology-intensive complex transcatheter therapies to transplant services, critical care, post-op rehab services as well as a significant footprint in preventive cardiac care through India's first AI driven cardiac risk prediction and disease prevention program- AICVD.

Dr. Prathap C. Reddy, Chairman of Apollo said "Having been a practicing cardiologist, I have been particularly invested in the growth and development of Cardiac Sciences at Apollo. Our first angioplasty and bypass surgery in 1986 marked the beginning of an incredible journey. Since then, our relentless commitment to healthcare involving adoption of the latest and safest methods with ethical execution and wide reach have helped us perform over 200,000 cardiac surgeries and over 300,000 angioplasties across Apollo Hospitals Group with millions of patients under a long-term cardiac care plan."

Dr Sangita Reddy, Joint Managing Director, Apollo said " Our next frontier is the battle against the NCD epidemic where we aim to stem the incidence of cardiovascular diseases and ensure early detection. . Apollo has launched a first-of-its kind artificial intelligence (AI) driven personalised preventive health program called 'ProHealth'. The need of the hour is true personalisation and prediction accompanied with ongoing health mentorship. Our revolutionary cardiac risk prediction tool, AICVD, has shown that one can expect a 90% predictive success in detecting coronary artery disease 10 years in advance. This information can be vital and life-changing in terms of preventing and managing heart disease proactively. We are happy to share this risk prediction model with everyone including the government since it would be a valuable tool in population health"